Principles of early drug discovery
Top Cited Papers
- 22 February 2011
- journal article
- review article
- Published by Wiley in British Journal of Pharmacology
- Vol. 162 (6), 1239-1249
- https://doi.org/10.1111/j.1476-5381.2010.01127.x
Abstract
Developing a new drug from original idea to the launch of a finished product is a complex process which can take 12-15 years and cost in excess of $1 billion. The idea for a target can come from a variety of sources including academic and clinical research and from the commercial sector. It may take many years to build up a body of supporting evidence before selecting a target for a costly drug discovery programme. Once a target has been chosen, the pharmaceutical industry and more recently some academic centres have streamlined a number of early processes to identify molecules which possess suitable characteristics to make acceptable drugs. This review will look at key preclinical stages of the drug discovery process, from initial target identification and validation, through assay development, high throughput screening, hit identification, lead optimization and finally the selection of a candidate molecule for clinical development.Keywords
This publication has 24 references indexed in Scilit:
- HTS and hit finding in academia – from chemical genomics to drug discoveryDrug Discovery Today, 2009
- Knowledge based identification of MAO-B selective inhibitors using pharmacophore and structure based virtual screening modelsEuropean Journal of Medicinal Chemistry, 2009
- Use of Primary Human Cells in High-Throughput ScreensPublished by Springer Science and Business Media LLC ,2009
- The promises and pitfalls of RNA-interference-based therapeuticsNature, 2009
- Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analysesNature Reviews Neuroscience, 2008
- An SCN9A channelopathy causes congenital inability to experience painNature, 2006
- High-Throughput Screening: Update on Practices and SuccessSLAS Discovery, 2006
- Ablation of MEKK4 Kinase Activity Causes Neurulation and Skeletal Patterning Defects in the Mouse EmbryoMolecular and Cellular Biology, 2005
- Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic painPain, 2005
- Analgesic profile of intrathecal P2X3 antisense oligonucleotide treatment in chronic inflammatory and neuropathic pain states in ratsPain, 2002